HeartSciences Inc 10-Q for FY2024 Q1

HeartSciences Inc. (HSCS)

10-Q 2023-09-14 For: 2023-07-31

Added on April 06, 2026

About this 10-Q

HeartSciences Inc filed this 10-Q on September 14, 2023, covering the quarter ended July 31, 2023 (FY2024 Q1).

Headline figures

Quarter ended July 31, 2023, as reported in this filing, compared with the same period a year earlier where the filing states it.

Net loss: $1.37M; compared with a net loss of $1.57M a year earlier
Diluted EPS: -$0.13; compared with -$0.28 a year earlier

Search and read filings like this one from Claude or ChatGPT with the SEC filings MCP server →


Texas	26-1344466
( State or other jurisdiction of incorporation or organization)	(I.R.S. Employer Identification No.)

550 Reserve Street, Suite 360 Southlake, Texas	76092
(Address of principal executive offices)	(Zip Code)


Title of each class	Trading Symbol(s)	Name of each exchange on which registered
Common Stock	HSCS	The Nasdaq Stock Market LLC
Warrants	HSCSW	The Nasdaq Stock Market LLC


Large accelerated filer	☐	Accelerated filer	☐
Non-accelerated filer	☒	Smaller reporting company	☒
Emerging growth company	☒


		Page

PART I.	FINANCIAL INFORMATION

Item 1.	Condensed Unaudited Financial Statements:
	Condensed Balance Sheets as of July 31, 2023 and April 30, 2023	1
	Condensed Statements of Operations for the three ended July 31, 2023 and 2022	2
	Condensed Statements of Stockholders' Equity (Deficit) for the three months ended July 31, 2023 and 2022	3
	Condensed Statements of Cash Flows for the three months ended July 31, 2023 and 2022	4
	Notes to the Condensed Unaudited Financial Statements	5
Item 2.	Management’s Discussion and Analysis of Financial Condition and Results of Operations	17
Item 3.	Quantitative and Qualitative Disclosures About Market Risk	21
Item 4.	Controls and Procedures	21

PART II.	OTHER INFORMATION	23

Item 1.	Legal Proceedings	23
Item 1A.	Risk Factors	23
Item 2.	Unregistered Sales of Equity Securities and Use of Proceeds	23
Item 3.	Defaults Upon Senior Securities	23
Item 4.	Mine Safety Disclosures	23
Item 5.	Other Information	23
Item 6.	Exhibits	24
Signatures		27


	July 31,			April 30,
	2023			2023
	(Unaudited)
ASSETS
CURRENT ASSETS:
Cash and cash equivalents	$	575,654		$	1,660,467
Inventory		676,359			676,359
Prepaid expenses		452,961			143,460
Other current assets		40,374			40,374
Deferred offering costs		283,749			175,921
Total current assets		2,029,097			2,696,581

Property and equipment, net		59,000			61,428
Right-of-use assets, net		509,726			529,224

TOTAL ASSETS	$	2,597,823		$	3,287,233

LIABILITIES AND STOCKHOLDERS' EQUITY (DEFICIT)
CURRENT LIABILITIES
Accounts payable	$	454,840		$	631,369
Accrued expenses		630,979			623,391
Operating lease liabilities		70,871			29,535
Current portion of notes payable		500,000			500,000
Other current liabilities		241,098			48,596
Total current liabilities		1,897,788			1,832,891

LONG-TERM LIABILITIES
Notes payable		500,000			500,000
Accrued expenses		207,592			187,450
Operating lease liabilities, long-term		512,145			536,335
Total long-term liabilities		1,219,737			1,223,785

TOTAL LIABILITIES		3,117,525			3,056,676

COMMITMENTS AND CONTINGENCIES (NOTE 2, 4-6, and 8)
STOCKHOLDERS (DEFICIT) EQUITY
Series A, B, and C convertible preferred stock, $0.001 par value, 20,000,000 shares authorized and 620,000 designated; 380,440 shares issued and outstanding as of July 31, 2023 and 380,871 shares issued and outstanding as of April 30, 2023.		380			381
Common stock, $0.001 par value, 500,000,000 shares authorized; 10,670,980 shares issued and outstanding as of July 31, 2023 and 10,118,440 shares issued and outstanding as of April 30, 2023.		10,671			10,118
Additional paid-in capital		61,593,300			60,977,256
Accumulated deficit		(62,124,053	)		(60,757,198	)
TOTAL STOCKHOLDERS (DEFICIT) EQUITY		(519,702	)		230,557
TOTAL LIABILITIES AND STOCKHOLDERS (DEFICIT) EQUITY	$	2,597,823		$	3,287,233


☒	QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934


☐	TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934


	Three Months Ended July 31,
	2023			2022
	(Unaudited)
Revenue	$	—		$	3,200

Cost of sales		—			2,036

Gross margin		—			1,164

Operating expenses:
Research and development		565,632			434,198
Selling, general and administrative		765,023			997,063
Total operating expenses		1,330,655			1,431,261

Loss from operations		(1,330,655	)		(1,430,097	)

Other income (expense)
Interest expense		(36,260	)		(143,607	)
Other income		60			401
Total other expense		(36,200	)		(143,206	)

Net loss	$	(1,366,855	)	$	(1,573,303	)

Net loss per share, basic and diluted	$	(0.13	)	$	(0.28	)

Weighted average common shares outstanding, basic and diluted		10,331,505			5,645,230


	Series A Convertible Preferred Stock						Series B Convertible Preferred Stock						Series C Convertible Preferred Stock						Total Convertible Preferred			Common Stock				Additional Paid-in			Accumulated			Total Stockholder's
	Shares			Amount			Shares			Amount			Shares			Amount			Stock			Shares		Amount		Capital			Deficit			Equity (Deficit)


BALANCE AT APRIL 30, 2023		—		$	—			—		$	—			380,871		$	381		$	381			10,118,440	$	10,118	$	60,977,256		$	(60,757,198	)	$	230,557

Sale of common stock, net of fees		—			—			—			—			—			—			—			441,906		442		391,508			—			391,950

Common stock issued for consulting services		—			—			—			—			—			—			—			108,696		109		99,891			—			100,000

Common stock issued upon conversion of Series C Convertible Preferred Stock		—			—			—			—			(431	)		(1	)		(1	)		1,938		2		(1	)		—			—

Stock based compensation - management & other employees		—			—			—			—			—			—			—			—		—		124,646			—			124,646

Net loss		—			—			—			—			—			—			—			—		—		—			(1,366,855	)		(1,366,855	)

BALANCE AT JULY 31, 2023		—		$	—			—		$	—			380,440		$	380		$	380			10,670,980	$	10,671	$	61,593,300		$	(62,124,053	)	$	(519,702	)


BALANCE AT APRIL 30, 2022		10,000		$	10			10,000		$	10			463,265		$	463		$	483			3,323,942	$	3,323	$	48,343,305		$	(54,402,908	)	$	(6,055,797	)

Sale of common stock and warrants, net of fees		—			—			—			—			—			—			—			1,500,000		1,500		5,193,240			—			5,194,740

Common stock issued upon conversion of $1.5M Notes		—			—			—			—			—			—			—			909,071		909		1,499,091			—			1,500,000

Common stock issued upon conversion of Bridge Notes and accrued interest		—			—			—			—			—			—			—			1,544,114		1,544		3,617,160			—			3,618,704

Common stock issued upon conversion of Series A and B Convertible Preferred Stock		(10,000	)		(10	)		(10,000	)		(10	)		—			—			(20	)		703,290		703		(683	)		—			—

Common stock issued upon conversion of Series C Convertible Preferred Stock		—			—			—			—			(50,676	)		(50	)		(50	)		193,958		194		(144	)		—			—

Stock based compensation - management & other employees		—			—			—			—			—			—			—			—		—		145,722			—			145,722

Warrants issued in IPO		—			—			—			—			—			—			—			—		—		17,250			—			17,250

Warrants issued to non-employees		—			—			—			—			—			—			—			—		—		39,953			—			39,953

Net loss		—			—			—			—			—			—			—			—		—		—			(1,573,303	)		(1,573,303	)

BALANCE AT JULY 31, 2022		—		$	—			—		$	—			412,589		$	413		$	413			8,174,375	$	8,173	$	58,854,894		$	(55,976,211	)	$	2,887,269


	Number of Shares
Issuance of Common Stock under Equity Line		441,906
Issuance of Common Stock as payment for consulting services rendered		108,696
Conversion of Series C convertible preferred stock to common stock		1,938
Issued during the three months ended July 31, 2023		552,540

Summary table of common stock share transactions:
Balance at April 30, 2023		10,118,440
Issued in Fiscal 2024		552,540
Balance at July 31, 2023		10,670,980


	Warrants Outstanding and Exercisable			Exercise Price Per Share		Weighted Average Strike Price per Share
Balance, April 30, 2023		2,590,342		$0.0001-$15.18		$	3.73
Forfeited		(7,688	)	$	3.47
Balance, July 31, 2023		2,582,654		$0.0001-$15.18		$	3.73


	Number of Options Outstanding			Weighted Average Exercise Price		Average Remaining Contractual Life (in years)
Outstanding - April 30, 2023		1,182,912		$	3.29		8.6
Options granted		—			—		—
Options forfeited		(114,545	)		3.04		—
Outstanding - July 31, 2023		1,068,367		$	2.24		8.9

Non-vested at July 31, 2023		896,462		$	0.98		9.6
Vested at July 31, 2023		171,905		$	11.03		3.5


	July 31,
	2023
Right-of-use assets	$	509,726

Lease liabilities, current	$	70,871
Lease liabilities, net of current portion		512,145
Total lease liabilities	$	583,016

Weighted average remaining term (in years)		4.8
Weighted average discount rate		12	%


2024	$	98,053
2025		161,164
2026		165,190
2027		169,307
2028		188,052
Total future lease payments		781,766
Less imputed interest		(198,750	)
Total operating lease liabilities	$	583,016


	Three Months Ended July 31,
	2023			2022			$ Change			% Change
	(In thousands, except percentages, unaudited)
Revenue	$	—		$	3		$	(3	)		(100	)%
Cost of sales		—			2			(2	)		(100	)%
Gross margin		—			1			(1	)		(100	)%
Operating expenses:
Research and development		566			434			131			30	%
Selling, general and administrative		765			997			(232	)		(23	)%
Total operating expenses		1,331			1,431			(101	)		(7	)%
Loss from operations		(1,331	)		(1,430	)		99			(7	)%
Interest expense		(36	)		(144	)		107			(75	)%
Other income (expense), net		(36	)		(144	)		107			(75	)%
Net loss	$	(1,367	)	$	(1,574	)	$	207			(13	)%


	July 31,			April 30,
	2023			2023
Raw materials	$	322,996		$	322,996
Sub-assemblies		347,436			347,436
Work in progress		21,741			21,741
Finished goods		28,662			28,662
Reserve for obsolescence		(44,476	)		(44,476	)
Total Inventory	$	676,359		$	676,359


	July 31,			April 30,
	2023			2023
Equipment	$	402,830		$	397,920
Furniture & fixtures		102,563			102,563
Leasehold improvements		32,812			32,812
Total		538,205			533,295
Less: Accumulated depreciation		(479,205	)		(471,867	)
Property and equipment, net	$	59,000		$	61,428


	July 31,			April 30,
	2023			2023
Deferred tax assets (liabilities):

Net operating loss carryforwards	$	10,268,546		$	9,701,650
Start-up costs		909,729			934,999
Stock option and warrant payments		564,843			538,669
Accumulated depreciation		(3,168	)		(3,111	)
Research and development credits		255,600			255,600
Research and development warrants		21,488			21,488
Total deferred tax assets, net		12,017,038			11,449,295
Valuation Allowance		(12,017,038	)		(11,449,295	)
Net Deferred Tax Assets	$	—		$	—


	Heart Test Laboratories, Inc.

Date: September 14, 2023	By:	/s/ Andrew Simpson
	Name:	Andrew Simpson
	Title:	President, Chief Executive Officer, and Chairman of the Board of Directors (Principal Executive Officer)

Date: September 14, 2023	By:	/s/ Danielle Watson
	Name:	Danielle Watson
	Title:	Chief Financial Officer and Treasurer (Principal Financial and Accounting Officer)


	Three Months Ended July 31,
U.S. dollars, in thousands	2023			2022
	(Unaudited)
Net cash used in operating activities	$	(1,404	)	$	(1,812	)
Net cash (used in) provided by investing activities	$	(5	)	$	(7	)
Net cash provided by financing activities	$	324		$	5,173
Net change in cash and cash equivalents during the period	$	(1,085	)	$	3,354


Exhibit Number		Description
1.1		Underwriting Agreement dated June 15, 2022 by and between the Heart Test Laboratories, Inc. and The Benchmark Company, LLC (incorporated by reference to Exhibit 1.1 to our Current Report on Form 8-K filed on June 15, 2022)
3.1		Amended and Restated Certificate of Formation of Heart Test Laboratories, Inc. (incorporated by reference to Exhibit 3.1 to our Registration Statement on Form S-1 filed May 17, 2022)
3.2		Certificate of Designations, Number, Voting Power, Preferences and Rights of Series C Convertible Preferred Stock of Heart Test Laboratories, Inc. (incorporated by reference to Exhibit 3.2 to our Registration Statement on Form S-1 filed May 17, 2022)
3.3		Second Amended and Restated Bylaws of Heart Test Laboratories, Inc. (incorporated by reference to Exhibit 3.3 to our Registration Statement on Form S-1 filed May 17, 2022)
3.4		Form of Certificate of Amendment to Amended and Restated Certificate of Formation of Heart Test Laboratories, Inc. (incorporated by reference to Exhibit 3.4 to Amendment No. 1 to our Registration Statement on Form S-1 filed June 6, 2022)
3.5		Certificate of Amendment to Amended and Restated Certificate of Formation of Heart Test Laboratories, Inc., as amended (incorporated by reference to Exhibit 3.1 to our Current Report on Form 8-K filed June 23, 2022)
4.1		Form of Registration Rights Agreement by and between Heart Test Laboratories, Inc. and Buyers listed as signatories thereto, dated December 22, 2021 (incorporated by reference to Exhibit 4.2 to our Registration Statement on Form S-1 filed May 17, 2022)
4.2		Form of Registration Rights Agreement by and among Heart Test Laboratories, Inc. and the parties listed as signatories thereto related to the Series C Preferred Stock (incorporated by reference to Exhibit 4.3 to our Registration Statement on Form S-1 filed May 17, 2022)
4.3		Form of Bridge Warrant (incorporated by reference to Exhibit 4.4 to our Registration Statement on Form S-1 filed May 17, 2022)
4.4		Form of Pre-Funded Warrant (incorporated by reference to Exhibit 4.5 to our Registration Statement on Form S-1 filed May 17, 2022)
4.5		Form of $1M Lender Warrant and $1.5M Lender Warrant (incorporated by reference to Exhibit 4.6 to our Registration Statement on Form S-1 filed May 17, 2022)
4.6		Form of Investor Warrant (incorporated by reference to Exhibit 4.7 to our Registration Statement on Form S-1 filed May 17, 2022)
4.7		Representative’s Warrant Agreement issued June 17, 2022 (incorporated by reference to Exhibit 4.1 to our Current Report on Form 8-K filed June 23, 2022)
4.8		Warrant Agent Agreement dated June 17, 2022 between Heart Test Laboratories, Inc. and American Stock Transfer & Trust Company, LLC (incorporated by reference to Exhibit 4.2 to our Current Report on Form 8-K filed June 23, 2022)
4.9		Form of Certificated Warrant (incorporated by reference to Exhibit 4.10 to Amendment No. 2 to our Registration Statement on Form S-1 filed June 10, 2022)
4.10		Amendment No. 1 to Bridge Warrants dated September 8, 2022 (incorporated by reference to Exhibit 4.1 to our Current Report on Form 8-K, filed with the SEC on September 9, 2022)
4.11		Form of Amendment No. 2 to Bridge Warrants dated February 3, 2023 (incorporated by reference to Exhibit 4.1 to our Current Report on Form 8-K, filed with the SEC on February 3, 2022)
4.12		Form of Amended and Restated Warrant to Purchase Common Stock, as amended through February 3, 2023 (incorporated by reference to Exhibit 4.1 to our Current Report on Form 8-K, filed with the SEC on February 22, 2023)
4.13		Form of Pre-Funded Warrant, issued pursuant to Amendment No. 2 to Warrants to Purchase Common Stock (incorporated by reference to Exhibit 4.2 to our Current Report on Form 8-K/A, filed with the SEC on March 14, 2023)
4.14		Form of Warrant to Purchase Common Stock dated September 7, 2023 (incorporated by reference to Exhibit 4.1 our Current Report on Form 8-K, filed with the SEC on September 7, 2023)
10.1		MyoVista Technology Agreement, by and between Heart Test Laboratories, Inc. and Guangren “Gary” Chen, dated December 31, 2013 (incorporated by reference to Exhibit 10.1 to our Registration Statement on Form S-1 filed May 17, 2022)
10.2		First Amendment of MyoVista Technology Agreement by and between Heart Test Laboratories, Inc. and Guangren “Gary” Chen, dated March 13, 2017 (incorporated by reference to Exhibit 10.2 to our Registration Statement on Form S-1 filed May 17, 2022)
10.3		Master Assignment by and between Heart Test Laboratories, Inc. and Guangren “Gary” Chen, dated January 1, 2014 (incorporated by reference to Exhibit 10.3 to our Registration Statement on Form S-1 filed May 17, 2022)
10.4		Security Agreement and Pledge by and between Heart Test Laboratories, Inc. and Guangren “Gary” Chen, dated March 14, 2014 (incorporated by reference to Exhibit 10.4 to our Registration Statement on Form S-1 filed May 17, 2022)


10.5		Evaluation, Option and License Agreement by and between Heart Test Laboratories, Inc. and The University Court of The University of Glasgow, dated June 2, 2015 (incorporated by reference to Exhibit 10.5 to our Registration Statement on Form S-1 filed May 17, 2022)
10.6		Exercise of Option Agreement by and between Heart Test Laboratories, Inc. and The University Court of The University of Glasgow, dated December 23, 2015 (incorporated by reference to Exhibit 10.6 to our Registration Statement on Form S-1 filed May 17, 2022)
10.7		$130K Note by and between Heart Test Laboratories, Inc. and Front Range Ventures, LLC, dated August 12, 2019 (incorporated by reference to Exhibit 10.7 to our Registration Statement on Form S-1 filed May 17, 2022)
10.8		$1M Loan and Security Agreement by and among Heart Test Laboratories, Inc., Front Range Ventures, LLC and John Q. Adams, Sr., dated April 24, 2020 (incorporated by reference to Exhibit 10.8 to our Registration Statement on Form S-1 filed May 17, 2022)
10.9		Amendment No. 1 to the $1M Loan and Security Agreement, dated September 30, 2021 (incorporated by reference to Exhibit 10.9 to our Registration Statement on Form S-1 filed May 17, 2022)
10.10		Amendment No. 2 to the $1M Loan and Security Agreement, dated November 3, 2021 (incorporated by reference to Exhibit 10.10 to our Registration Statement on Form S-1 filed May 17, 2022)
10.11		Form of $1.5M Note (incorporated by reference to Exhibit 10.11 to our Registration Statement on Form S-1 filed May 17, 2022)
10.12		Form of Amendment No. 1 to the Form of $1.5M Note by and among Heart Test Laboratories, Inc. and the Requisite Noteholders, dated November 2, 2021 (incorporated by reference to Exhibit 10.12 to our Registration Statement on Form S-1 filed May 17, 2022)
10.13		Form of Securities Purchase Agreement by and between Heart Test Laboratories, Inc. and Purchasers listed as signatories thereto, dated December 22, 2021 (incorporated by reference to Exhibit 10.13 to our Registration Statement on Form S-1 filed May 17, 2022)
10.14		Form of Bridge Note (incorporated by reference to Exhibit 10.14 to our Registration Statement on Form S-1 filed May 17, 2022)
10.15		Consulting Agreement by and between Heart Test Laboratories, Inc. and Kyngstone Limited, Inc., dated June 25, 2013 (incorporated by reference to Exhibit 10.15 to our Registration Statement on Form S-1 filed May 17, 2022)
10.16		FRV Side Letter by and between Heart Test Laboratories, Inc. and Front Range Ventures, LLC, dated April 10, 2019 (incorporated by reference to Exhibit 10.16 to Amendment No. 1 to our Registration Statement on Form S-1 filed June 6, 2022)
10.17		Amended and Restated Employment Agreement by and between Heart Test Laboratories, Inc. and Mark Hilz, dated April 5, 2022 (incorporated by reference to Exhibit 10.17 to our Registration Statement on Form S-1 filed May 17, 2022)
10.18		Employment Agreement by and between Heart Test Laboratories, Inc. and Andrew Simpson, dated April 5, 2022 (incorporated by reference to Exhibit 10.18 to our Registration Statement on Form S-1 filed May 17, 2022)
10.19		Form of Amendment No. 3 to the $1M Loan and Security Agreement, dated May 2022 (incorporated by reference to Exhibit 10.19 to our Registration Statement on Form S-1 filed May 17, 2022)
10.20		Form of Amendment No. 2 to the Form of $1.5M Note by and among Heart Test Laboratories, Inc. and the Requisite Noteholders, dated May 2022 (incorporated by reference to Exhibit 10.20 to our Registration Statement on Form S-1 filed May 17, 2022)
10.21		Form of Time-Based Vesting Nonstatutory Stock Option Agreement of Heart Test Laboratories, Inc. (incorporated by reference to Exhibit 10.21 to our Registration Statement on Form S-1 filed May 17, 2022)
10.22		Form of Performance-Based Vesting Nonstatutory Stock Option Agreement of Heart Test Laboratories, Inc (incorporated by reference to Exhibit 10.22 to our Registration Statement on Form S-1 filed May 17, 2022)
10.23		Amendment No. 4 to the $1M Loan and Security Agreement, dated January 24, 2023 (incorporated by reference to Exhibit 10.1 to our Current Report on Form 8-K, filed with the SEC on January 24, 2023)
10.24		Purchase Agreement, dated as of March 10, 2023, by and between Heart Test Laboratories, Inc. and Lincoln Park (incorporated by reference to Exhibit 10.1 to the Current Report on Form 8-K, filed with the SEC on March 10, 2023)
10.25		Registration Rights Agreement, dated as of March 10, 2023, by and between Heart Test Laboratories, Inc. and Lincoln Park (incorporated by reference to Exhibit 10.2 to the Current Report on Form 8-K, filed with the SEC on March 13, 2023)
10.26†		Heart Test Laboratories, Inc. 2023 Equity Incentive Plan (incorporated by reference to Exhibit 10.1 to the Current Report on Form 8-K, filed with the SEC on March 16, 2023)
10.27†		Form of Heart Test Laboratories, Inc.'s Incentive Stock Option Agreement under Heart Test Laboratories Inc.’s 2023 Equity Incentive Plan (incorporated by reference to Exhibit 10.1 to the Current Report on Form 8-K, filed with the SEC on March 23, 2023)
10.28†		Form of Heart Test Laboratories Inc.’s Non-Qualified Stock Option Agreement under Heart Test Laboratories Inc.’s 2023 Equity Incentive Plan (incorporated by reference to Exhibit 10.2 to the Current Report on Form 8-K, filed with the SEC on March 23, 2023)


10.29		Amendment No. 2 License Agreement by and between Heart Test Laboratories, Inc. and The University Court of The University of Glasgow, dated March 31, 2023 (incorporated by reference to Exhibit 10.29 to the Annual Report on Form 10-K, filed with the SEC on July 19, 2023)
10.30		Senior Unsecured Promissory Drawdown Loan Note by and among Heart Test Laboratories, Inc., and Matthews Southwest Holdings, Inc., dated September 6, 2023 and executed on September 7, 2023 (incorporated by reference to Exhibit 10.1 our Current Report on Form 8-K, filed with the SEC on September 7, 2023)
31.1*		Certification of Principal Executive Officer Pursuant to Rules 13a-14(a) and 15d-14(a) under the Securities Exchange Act of 1934, as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002
31.2*		Certification of Principal Financial Officer Pursuant to Rules 13a-14(a) and 15d-14(a) under the Securities Exchange Act of 1934, as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002
32.1**		Certification of Principal Executive Officer Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002
32.2**		Certification of Principal Financial Officer Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002
104		Cover Page Interactive Data File (embedded within the Inline XBRL document)
101.INS*		Inline XBRL Instance Document
101.SCH*		Inline XBRL Taxonomy Extension Schema Document
101.CAL*		Inline XBRL Taxonomy Extension Calculation Linkbase Document
101.DEF*		Inline XBRL Taxonomy Extension Definition Linkbase Document
101.LAB*		Inline XBRL Taxonomy Extension Label Linkbase Document
101.PRE*		Inline XBRL Taxonomy Extension Presentation Linkbase Document